Interview, Fireside Chat
Weighing the GLP-1 Market
- The global addressable market for GLP-1s involves over one billion people with obesity, though actual adoption may be significantly constrained by insurance coverage limitations.
- Non-response or minimal response to GLP-1 medications is reported in 10 to 15 percent of study populations, with clinical observations in diverse practices estimating this figure closer to 20 percent.
- Bariatric surgery remains the most efficacious treatment for severe obesity and metabolic disease, inducing type 2 diabetes remission in over 80 percent of patients within the first four to five days.
- Competitive pressure in the private insurance market is expected to result in 100 percent of employer-sponsored insurers in Massachusetts covering anti-obesity medications.
- Goldman Sachs research projects that if 40 percent of Americans with obesity utilize GLP-1s, net government costs could reach $800 billion annually, a figure comparable to the total size of the Medicare program.
- A Goldman Sachs model accounts for estimated savings of approximately $200 billion annually from reduced obesity and diabetes-related illnesses, resulting in a net projected government cost of $800 billion per year.
- Future U.S. economic growth may see meaningful positive impacts from the widespread adoption of GLP-1 drugs and subsequent health improvements, contingent on continued investment, innovation, and price reductions.
- Diverting government spending from drug coverage to public R&D via the NIH is predicted to drive greater overall drug innovation than maintaining capital within private pharmaceutical companies.
- Current public R&D spending in the U.S. has declined to less than 0.6 percent of GDP, a level that currently ranks the nation 14th globally.
- The Inflation Reduction Act has established a framework allowing Medicare to negotiate drug prices for a limited drug set, indicating a potential positive trend for future price regulation efforts.
- Market competition is expected to eventually drive down GLP-1 prices, although this process is currently hindered by patent protections and legal extensions.
- For the populations deriving the most benefit, the social value of GLP-1 treatment is estimated at approximately $7,000 annually.
- Forward-looking statements regarding projected results and economic impacts are subject to uncertainty, with no guarantee that anticipated outcomes will be achieved.